In re HIV Antitrust Litigation

District Court, N.D. California·Decided April 20, 2023·No. 3:19-cv-02573·Unknown

Opinion

IN RE HIV ANTITRUST LITIGATION. Case No. 19-cv-02573-EMC

ORDER RE CHOICE OF LAW FOR Docket Nos. 1721, 1723

Currently pending before the Court is a dispute between Defendants and United as to which state’s laws govern United’s state law claims.1 United asserts that its claims are governed by Minnesota law because it overpaid for the HIV drugs at issue from Minnesota where it is based – notwithstanding the fact that many of its insureds who requested the drugs, received the drugs, and used the drugs live outside of Minnesota, including in states that did not repeal Illinois Brick.2 Defendants argue that Minnesota law does not apply across the board and that the law that governs is that of the state where a given insured lives. If Defendants are correct, then United could not seek damages where its claims are related to an insured who lives in a non-repealer state. Having considered the parties’ briefs and the oral argument of counsel, the Court finds United’s position more persuasive and thus holds that United’s claims are governed by the law of 1 The Court addresses here only those claims that United brings as an indirect purchaser. United has been assigned some claims by direct purchasers.

2 In Illinois Brick Co. v. Illinois, the Supreme Court held that only “the overcharged direct purchaser, and not others in the chain of manufacture or distribution” may bring an anticompetitive conduct claim under the Clayton Act. 431 U.S. 720, 729 (1977). Some states Minnesota. United is a multinational managed healthcare and insurance company headquartered in Minnesota. See United Compl. ¶ 20. United alleges that it was injured when it was made to pay overcharges related to HIV drugs that were caused by Defendants’ anticompetitive conduct. See id. ¶ 19. According to United, when one of its insured individuals (hereinafter, a “member”) receives an HIV drug from a pharmacy, the member pays only their co–pay obligation. United pays for the remainder of the cost of the drug. Specifically, United receives an invoice from its Pharmacy Benefits Manager (PBM), a third–party intermediary responsible for processing prescription drug claims. United receives and then pays the invoice from its headquarters in Minnesota, regardless of where the member received the drug. See id. ¶ 332. United seeks to recover damages under the Minnesota Antitrust Act which makes “[a] contract, combination, or conspiracy between two or more persons in unreasonable restraint of trade or commerce . . . unlawful,” and applies to “any contract, combination, or conspiracy, wherever created, formed, or entered into, . . . whenever any of the foregoing affects the trade or commerce of [Minnesota].” Minn. Stat. § 325D.51; 325D.54(b). Crucially, Minnesota is a repealer state. That is, unlike federal antitrust law, Minnesota law provides that indirect purchasers may sue for damages under state law antitrust theories. See Minn. Stat. § 325D.57. United seeks to recover only damages from the overcharges it paid from its Minnesota headquarters. See United Brief at 1. It does not seek any recovery related to their members’ co– pay obligations. See id. In their sixth motion in limine, Defendants moved to exclude evidence and argument related to damages which Defendants claimed Plaintiffs, including United, could not recover as a matter of law. See Mot. at 1. According to Defendants, United’s damages claims are flawed because they are based on Minnesota law applying across the board – i.e., even where United contend United cannot sue as an indirect purchaser with respect to claims for drugs sent to members in non-repealer states. In its order on the in limine motions, the Court acknowledged that it had previously, for the EPPs, rejected application of one state’s law across the board – i.e., California. But, the Court explained, it had reached that conclusion based on a California choice-of-law analysis. “[H]ere, there should be a choice-of-law analysis under Minnesota law,” Docket No. 1716 (Order at 6) (emphasis omitted), because United had initiated its lawsuit in Minnesota federal court prior to transfer of the action to this Court. See Sarver v. Chartier, 813 F.3d 891, 897 (9th Cir. 2016) (“Typically, ‘a federal court sitting in diversity applies the conflict-of-law rules of the state in which it sits.’ However, after a transfer under 28 U.S.C. § 1404 the choice-of-law rules of the transferor court apply.”). The Court ordered supplemental briefing on what result should obtain under a Minnesota choice–of–law analysis. When conducting a conflict–of–laws analysis under Minnesota law, “a court must first determine whether there is an actual conflict between the legal rules of the two states.” Nodak Mut. Ins. Co. v. Am. Fam. Mut. Ins. Co., 590 N.W.2d 670, 672 (Minn. Ct. App. 1999), aff'd, 604 N.W.2d 91 (Minn. 2000). If the court determines that there is a conflict, it next “must consider whether the rule of each state may be constitutionally applied.” Id. “[F]or a State's substantive law to be selected in a constitutionally permissible manner, that State must have a significant contact or significant aggregation of contacts, creating state interests, such that choice of its law is neither arbitrary nor fundamentally unfair.” Allstate Ins. Co. v. Hague, 449 U.S. 302, 312–13 (1981). Finally, if there is an actual conflict and the candidate states’ laws can be constitutionally applied, courts evaluate five “choice influencing factors” to determine which substantive law to apply. Jepson v. Gen. Cas. Co. of Wisconsin, 513 N.W.2d 467, 470 (Minn. 1994). Those factors are: (1) predictability of result; (3) simplification of the judicial task; (4) advancement of the forum's governmental interest; and (5) application of the better rule of law. Id. In delineating the “choice influencing factors,” the Minnesota Supreme Court has stressed:

Free access — add to your briefcase to read the full text and ask questions with AI

In re HIV Antitrust Litigation, (N.D. Cal. 2023).

In re HIV Antitrust Litigation (In re HIV Antitrust Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Illinois Brick Co. v. Illinois
431 U.S. 720 (Supreme Court, 1977)
Allstate Insurance v. Hague
449 U.S. 302 (Supreme Court, 1981)
Jepson v. General Casualty Co. of Wisconsin
513 N.W.2d 467 (Supreme Court of Minnesota, 1994)
Milkovich v. Saari
203 N.W.2d 408 (Supreme Court of Minnesota, 1973)
Hime v. State Farm Fire & Casualty Co.
284 N.W.2d 829 (Supreme Court of Minnesota, 1979)
Myers v. Government Employees Insurance Co.
225 N.W.2d 238 (Supreme Court of Minnesota, 1974)
Standal v. Armstrong Cork Co.
356 N.W.2d 380 (Court of Appeals of Minnesota, 1984)
Nodak Mutual Insurance Co. v. American Family Mutual Insurance Co.
590 N.W.2d 670 (Court of Appeals of Minnesota, 1999)
SCM Corp. v. Deltak Corp.
702 F. Supp. 1428 (D. Minnesota, 1988)
In Re Rezulin Products Liability Litigation
392 F. Supp. 2d 597 (S.D. New York, 2005)
Sgt. Jeffrey Sarver v. Nicolas Chartier
813 F.3d 891 (Ninth Circuit, 2016)
Chen v. Los Angeles Truck Centers, LLC
444 P.3d 727 (California Supreme Court, 2019)
Karen Stromberg v. Qualcomm Inc.
14 F.4th 1059 (Ninth Circuit, 2021)
Buder v. United States
7 F.3d 1382 (Eighth Circuit, 1993)
In re Baycol Products Litigation
218 F.R.D. 197 (D. Minnesota, 2003)
In re Wellbutrin XL Antitrust Litigation
282 F.R.D. 126 (E.D. Pennsylvania, 2011)